Release no 28/2010
Copenhagen and Oslo, 19th August, 2010
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today
announced that the Company publishes a prospectus, which has been prepared in
connection with the admission to trading and official listing on NASDAQ OMX
Copenhagen A/S of a total of 260,187,010 already issued shares of DKK 0.50
nominal value each issued on April 22nd, 2010 and registered in VP SECURITIES
A/S on May 27th to Trans Nova Investments Limited. No further shares in Affitech
A/S will be issued in connection with the publication of this prospectus.
Trans Nova's subscription of the Transaction Shares took place on April 21st,
2010. The Transaction Shares were registered with the Danish Commerce and
Companies Agency on April 22nd, 2010. The Offering was not underwritten. Trans
Nova has on May 27th 2010 received a dispensation from Danish Supervisory
Authority from the obligation to make a mandatory purchase offer to the
remaining shareholders in Affitech A/S
At the extraordinary general meeting held on May 5th, 2009, the shareholders in
the Company resolved to authorise the Company's Board of Directors to increase
the share capital during the period until December 31st, 2010 in one or more
issues by a nominal value of up to DKK 150,000,000 (300,000,000 Shares of DKK
0.50 each). This authorisation was used partly in connection with the capital
increase on 30th June, 2009, following which the authorisation comprised DKK
132.846.887.50 (265,633,775 Shares). Pursuant to Article 4.1 of the Company's
articles of association, the Board of Directors passed a resolution as part of
the Trans Nova Transaction on April 16th, 2010 to increase the Company's share
capital by issuance of the New Shares to the Cyprus based company Trans Nova. As
such it was a directed offering at market price of DKK 0.60 per Share of DKK
0.50 nominal value each without pre-emptive rights to the existing shareholders.
The prospectus is attached to the Danish version of this release in PDF format
in Danish and available at www.affitech.com. An English version of the
prospectus will be uploaded to www.affitech.com shortly.
--------------------------------------------------------------------------------
| For more information please contact Affitech A/S: |
--------------------------------------------------------------------------------
| Martin Welschof, Managing Director | Randi Krogsgaard, Corporate |
| | Communications |
| Tel # +47 95 12 81 37 | Tel # +45 2320 1001, e-mail: |
| | ir@affitech.com |
--------------------------------------------------------------------------------
About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company headquartered in Copenhagen, Denmark with R&D facilities in
Oslo, Norway. The company utilizes a range of proprietary antibody technologies
for the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to cell
surface molecules in situ. Several of the Company's proprietary product
candidates were generated by CBAS™. Further information is available at
www.affitech.com.
Disclaimer
This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
results of the financial condition and operations of Affitech A/S. There are
many factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements
and forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.
No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided herein,
and no claims shall be made by the recipient of this news release by virtue of
the information contained herein.